Latest California Healthline Stories
Uncertain Fate Of Health Law Giving Health Industry Heartburn
The effect of “repeal and replace” could have greatest consequences for hospitals. They accepted lower federal funding under the law because their uncompensated care was expected to fall as more people became insured.
Obamacare ‘Replacement’ Might Look Familiar
Republicans want to jettison the health law, but some features are already hardwired into the system.
Blue Shield Again Owes Californians Millions In Health Care Rebates
The insurer is on the hook for $25 million in refunds to about 240,000 enrollees with employer coverage.
California Releases Latest ‘Report Cards’ On Health Plans, Doctor Groups
Statewide ratings now also address health care costs with new data on average payments to doctors.
Are Blues’ Plans Benefiting Unfairly From Program To Offset Cost Of Sicker Patients?
Other insurers complain that Blue Cross Blue Shield plans have bloated overhead costs and reap too much from the Obamacare risk-adjustment fund, paid for by insurers. The companies deny it.
Expert Panel Recommends Expansion Of Services With No Cost Sharing For Women
The list of preventive services that insurers must cover without a co-pay could grow to include mammograms for younger women, testing that follows an irregular screening and birth control for men.
In Arizona, Health Law’s Gains And Losses Play In Presidential Race
Clinton has offered detailed plans to preserve and expand the law, while Trump has vowed to “repeal and replace Obamacare so quickly.”
Remember The ‘Public Option’? Insurance Commissioner Wants To Try It In California
California Insurance Commissioner Dave Jones says a publicly run health plan would bolster competition in the state. But some question whether it would lower premiums.
Governor Weighs Legislation On Surprise Medical Bills
The problem, known as balance billing, happens when patients are treated by an out-of-network professional at an in-network facility. Gov. Jerry Brown is expected to sign the legislation.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.